New HIV Regimen Shows Promise in ARTISTRY-1 & ARTISTRY-2 Trials | Healio

Denver – Recent data presented at the Conference on Retroviruses and Opportunistic Infections offer compelling support for a novel, single-tablet regimen as a viable alternative to more complex HIV treatment options. The findings, stemming from the ARTISTRY-1 and ARTISTRY-2 phase 3 trials, suggest that the combination of bictegravir and lenacapavir demonstrates high efficacy and a manageable safety profile for individuals already virally suppressed on existing therapies.

Simplifying HIV Treatment: A Focus on Single-Tablet Regimens

For many living with HIV, managing the virus involves a complex cocktail of medications. Single-tablet regimens have grow increasingly important in optimizing treatment, offering the convenience of a single daily dose which can improve adherence and, clinical outcomes. However, not everyone can benefit from currently available single-tablet options due to factors like drug resistance, intolerances, or contraindications. This creates a demand for expanded treatment choices tailored to individual patient needs.

ARTISTRY-1: Evaluating the Bictegravir/Lenacapavir Combination

The ARTISTRY-1 trial was designed as a blinded, active-controlled study to assess the effectiveness of switching to a once-daily single-tablet regimen of bictegravir (BIC) and lenacapavir (LEN) for adults with HIV who had already achieved viral suppression while on more complex antiretroviral therapy (ART). A total of 557 participants, with a median age of 60 and 18% identifying as women, were randomly assigned in a 2:1 ratio to either switch to the BIC/LEN combination (n=371) or continue their existing complex regimen (n=186).

The primary endpoint of the study focused on the proportion of patients experiencing a rebound in viral load – defined as HIV-1 RNA reaching 50 copies/mL or higher – at week 48. Researchers also closely monitored the incidence of adverse events. The results showed that 0.8% of participants in the BIC/LEN arm and 1.1% in the complex regimen group met this endpoint, demonstrating non-inferiority. A substantial majority – 96% and 93.5% respectively – maintained viral suppression below 50 copies/mL. Importantly, no participants developed emergent drug resistance. However, drug-related adverse events were reported more frequently in the BIC/LEN group (14.3%) compared to those continuing their complex regimen (1.6%).

ARTISTRY-2: Comparing to Bictegravir/Emtricitabine/Tenofovir Alafenamide

ARTISTRY-2 took a slightly different approach, comparing the BIC/LEN regimen directly to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), another commonly prescribed single-tablet regimen. This trial, also blinded and active-controlled, involved 574 participants (median age 49, 19% women) who had been virally suppressed on B/F/TAF for at least six months. Participants were randomized 2:1 to switch to BIC/LEN (n=383) or continue B/F/TAF (n=191).

Similar to ARTISTRY-1, the primary endpoint was the proportion of patients with HIV-1 RNA of 50 copies/mL or higher at week 48, with researchers also tracking treatment-emergent adverse events. At the 48-week mark, 1.3% of those on BIC/LEN and 1% on B/F/TAF reached the primary endpoint, again demonstrating non-inferiority. Viral suppression below 50 copies/mL was maintained by 93.5% of the BIC/LEN group and 90.6% of the B/F/TAF group. Notably, the incidence of both overall adverse events (75.2% vs. 73.8%) and drug-related adverse events (10.4% vs. 12%) were comparable between the two treatment groups.

What Does This Mean for People Living with HIV?

According to Dr. Eric G. Meissner, associate professor of medicine and director of HIV and hepatitis patient care and research at the Medical University of South Carolina, and principal investigator on ARTISTRY-2, these findings underscore the potential of BIC/LEN to expand treatment options for individuals with HIV. [email protected]. The convenience of a single-tablet regimen can significantly improve adherence, which is crucial for long-term viral suppression and overall health.

Dr. Chloe Orkin, professor and dean for healthcare transformation at the Queen Mary University of London and principal investigator on ARTISTRY-1, added that while single-tablet regimens have revolutionized HIV treatment, they aren’t universally applicable. [email protected]. Some individuals face challenges with existing combinations due to viral resistance, medication intolerances, or drug interactions, creating a demand for novel options that better address their specific needs and preferences.

Understanding the Study Limitations and Next Steps

It’s important to note that both ARTISTRY-1 and ARTISTRY-2 were conducted over a 48-week period. Longer-term follow-up studies are needed to assess the durability of these findings and to monitor for any potential delayed adverse effects. The trials focused on individuals who were already virally suppressed, meaning the results may not be directly applicable to those initiating HIV treatment. The trials also did not include a diverse representation of all populations living with HIV, so further research is needed to determine how the regimen performs across different demographic groups.

The researchers emphasize that these findings represent a significant step forward in expanding treatment options for people living with HIV. The next phase will likely involve ongoing monitoring of participants in the ARTISTRY trials, as well as potential submissions to regulatory agencies for approval of the BIC/LEN combination. Further research will also focus on identifying which individuals are most likely to benefit from this new regimen and on optimizing its use in clinical practice. For more information on HIV treatment options, individuals should consult with a qualified healthcare provider and refer to guidance from organizations like the Centers for Disease Control and Prevention and the World Health Organization.